{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T23:42:22Z","timestamp":1778542942446,"version":"3.51.4"},"reference-count":65,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"unspecified","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"NHMRC","doi-asserted-by":"crossref","award":["1196892"],"award-info":[{"award-number":["1196892"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000925","name":"NHMRC","doi-asserted-by":"crossref","award":["2017131"],"award-info":[{"award-number":["2017131"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP2001375"],"award-info":[{"award-number":["APP2001375"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,6,18]]},"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Current treatments for alcohol use disorders (AUD) have limited efficacy. A previous 28-day pilot trial of N-acetyl cysteine (NAC) vs placebo found NAC to be feasible and safe, with evidence of improvement on some measures of alcohol consumption. Thus, the primary aim of the NAC-AUD study is to examine the therapeutic and cost-effectiveness of NAC vs placebo in improving treatment outcomes for AUD. We will also examine the (i) effect of NAC vs placebo on mood, markers of liver injury, cognition and hangover symptoms; and (ii) predictors of any response.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and analysis<\/jats:title>\n                  <jats:p>This double-blind trial will randomise participants with AUD to a 12-week regimen of either NAC (2400\u2009mg\/day) or placebo. All participants will receive medical management. The primary drinking outcome will be the number of heavy drinking days (HDDs) per week, validated by phosphatidylethanol (PEth). Secondary alcohol-related outcomes will include standard drinks per drinking day (SDDD) per week and absence of any HDDs. Other secondary outcomes will include markers of liver injury, depression, anxiety, craving, hangover symptoms, cognition and blood oxidative stress markers. We will also examine the cost-efficacy of NAC vs placebo.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Ethics and dissemination<\/jats:title>\n                  <jats:p>Ethics approval for the study has been granted by The Sydney Local Health District Ethics Review Committee (X21-0342&amp; HREC2021\/ETH11614). There are no restrictions on publication from the sponsor or other parties.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT05408247\">NCT05408247<\/jats:ext-link>.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-091631","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T17:35:24Z","timestamp":1757352924000},"page":"e091631","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["N-acetyl cysteine for the treatment of alcohol use disorder: study protocol for a multi-site, double-blind randomised controlled trial (NAC-AUD study)"],"prefix":"10.1136","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct05408247","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05408247","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0868-9928","authenticated-orcid":false,"given":"Kirsten","family":"Morley","sequence":"first","affiliation":[{"name":"Specialty of Addiction Medicine, The University of Sydney School of Medicine, Sydney, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shalini","family":"Arunogiri","sequence":"additional","affiliation":[{"name":"Eastern Health Clinical School, Monash University, Box Hill, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason P","family":"Connor","sequence":"additional","affiliation":[{"name":"The University of Queensland, Saint Lucia, Queensland, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul J","family":"Clark","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Princess Alexandra Hospital, Brisbane, Queensland, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4902-9448","authenticated-orcid":false,"given":"Mary Lou","family":"Chatterton","sequence":"additional","affiliation":[{"name":"Monash University, Clayton, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Baillie","sequence":"additional","affiliation":[{"name":"Health Sciences, University of Sydney, Camperdown, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Slade","sequence":"additional","affiliation":[{"name":"Matilda Centre, The University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Berk","sequence":"additional","affiliation":[{"name":"Psychiatry, Deakin University Faculty of Health Medicine Nursing and Behavioural Sciences, Geelong, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Lubman","sequence":"additional","affiliation":[{"name":"Eastern Health Clinical School, Monash University, Box Hill, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul S","family":"Haber","sequence":"additional","affiliation":[{"name":"Specialty of Addiction Medicine, The University of Sydney School of Medicine, Sydney, New South Wales, Australia"},{"name":"Drug Health Services, Sydney Local Health District, Camperdown, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,9,8]]},"reference":[{"key":"2025090810351192000_15.9.e091631.1","unstructured":"World Health Organization . Global status report on alcohol and health 2018. World Health Organization; 2019."},{"key":"2025090810351192000_15.9.e091631.2","doi-asserted-by":"publisher","DOI":"10.5694\/MJA2.51254"},{"key":"2025090810351192000_15.9.e091631.3","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1080\/14656566.2021.1892641","article-title":"New approved and emerging pharmacological approaches to alcohol use disorder: a review of clinical studies","volume":"22","author":"Morley","year":"2021","journal-title":"Expert Opin Pharmacother"},{"key":"2025090810351192000_15.9.e091631.4","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1111\/add.15532","article-title":"Commentary on Donoghue: Low prescribing rates of pharmacotherapy for alcohol use disorder limit potential public health impact","volume":"116","author":"Morley","year":"2021","journal-title":"Addiction"},{"key":"2025090810351192000_15.9.e091631.5","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s40429-018-0211-1","article-title":"Pharmacotherapy for alcohol use disorder and alcoholic liver disease","volume":"5","author":"Stocklosa","year":"2018","journal-title":"Curr Addict Rep"},{"key":"2025090810351192000_15.9.e091631.6","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S2215-0366(18)30303-1","article-title":"Baclofen for the treatment of alcohol use disorder: the Cagliari Statement","volume":"5","author":"Agabio","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"2025090810351192000_15.9.e091631.7","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1192\/bjp.2018.13","article-title":"Baclofen in the treatment of alcohol dependence with or without liver disease: multisite, randomised, double-blind, placebo-controlled trial","volume":"212","author":"Morley","year":"2018","journal-title":"Br J Psychiatry"},{"key":"2025090810351192000_15.9.e091631.8","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.20230666"},{"key":"2025090810351192000_15.9.e091631.9","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1080\/13543784.2018.1501471","article-title":"N-acetyl cysteine in the treatment of alcohol use disorder in patients with liver disease: Rationale for further research","volume":"27","author":"Morley","year":"2018","journal-title":"Expert Opin Investig Drugs"},{"key":"2025090810351192000_15.9.e091631.10","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.redox.2015.07.012","article-title":"Effects of N-acetylcysteine, oral glutathione (GSH) and a novel sublingual form of GSH on oxidative stress markers: A comparative crossover study","volume":"6","author":"Schmitt","year":"2015","journal-title":"Redox Biol"},{"key":"2025090810351192000_15.9.e091631.11","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1111\/acer.13842","article-title":"Commonality of Ethanol and Nicotine Reinforcement and Relapse in Wistar-Derived UChB Rats: Inhibition by N-Acetylcysteine","volume":"42","author":"Quintanilla","year":"2018","journal-title":"Alcohol Clin Exp Res"},{"key":"2025090810351192000_15.9.e091631.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2020.08.002"},{"key":"2025090810351192000_15.9.e091631.13","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/acer.14992","article-title":"Central markers of neuroinflammation in alcohol use disorder: A meta-analysis of neuroimaging, cerebral spinal fluid, and postmortem studies","volume":"47","author":"Adams","year":"2023","journal-title":"Alcohol Clin Exp Res (Hoboken)"},{"key":"2025090810351192000_15.9.e091631.14","doi-asserted-by":"crossref","DOI":"10.3390\/antiox11101919","article-title":"The Status of Oxidative Stress in Patients with Alcohol Dependence: A Meta-Analysis","volume":"11","author":"Yang","year":"2022","journal-title":"Antioxidants (Basel)"},{"key":"2025090810351192000_15.9.e091631.15","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2018.00412","article-title":"Neurometabolite Levels in Alcohol Use Disorder Patients During Baclofen Treatment and Prediction of Relapse to Heavy Drinking","volume":"9","author":"Morley","year":"2018","journal-title":"Front Psychiatry"},{"key":"2025090810351192000_15.9.e091631.16","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.9609.1","article-title":"Glutamate plasticity woven through the progression to alcohol use disorder: a multi-circuit perspective","volume":"6","author":"Hwa","year":"2017","journal-title":"F1000Res"},{"key":"2025090810351192000_15.9.e091631.17","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/adb.12521","article-title":"Effect of N-acetylcysteine on motivation, seeking and relapse to ethanol self-administration","volume":"23","author":"Lebourgeois","year":"2018","journal-title":"Addict Biol"},{"key":"2025090810351192000_15.9.e091631.18","doi-asserted-by":"publisher","DOI":"10.1111\/acer.13031"},{"key":"2025090810351192000_15.9.e091631.19","doi-asserted-by":"publisher","DOI":"10.1007\/s11064-017-2218-8"},{"key":"2025090810351192000_15.9.e091631.20","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s40263-022-00907-3","article-title":"The Potential of N-Acetyl-L-Cysteine (NAC) in the Treatment of Psychiatric Disorders","volume":"36","author":"Bradlow","year":"2022","journal-title":"CNS Drugs"},{"key":"2025090810351192000_15.9.e091631.21","doi-asserted-by":"crossref","first-page":"39","DOI":"10.4088\/JCP.13m08411","article-title":"A randomized, placebo-controlled trial of N-acetylcysteine plus imaginal desensitization for nicotine-dependent pathological gamblers","volume":"75","author":"Grant","year":"2014","journal-title":"J Clin Psychiatry"},{"key":"2025090810351192000_15.9.e091631.22","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/jamapsychiatry.2016.0060","article-title":"N-Acetylcysteine in the Treatment of Excoriation Disorder: A Randomized Clinical Trial","volume":"73","author":"Grant","year":"2016","journal-title":"JAMA Psychiatry"},{"key":"2025090810351192000_15.9.e091631.23","doi-asserted-by":"publisher","DOI":"10.1179\/1351000215Y.0000000004"},{"key":"2025090810351192000_15.9.e091631.24","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.addbeh.2017.11.044","article-title":"The effect of N-acetylcysteine and working memory training on cocaine use, craving and inhibition in regular cocaine users: correspondence of lab assessments and Ecological Momentary Assessment","volume":"79","author":"Schulte","year":"2018","journal-title":"Addict Behav"},{"key":"2025090810351192000_15.9.e091631.25","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101005","article-title":"N-acetylcysteine (NAC) for methamphetamine dependence: A randomised controlled trial","volume":"38","author":"McKetin","year":"2021","journal-title":"EClinicalMedicine"},{"key":"2025090810351192000_15.9.e091631.26","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.2823","article-title":"The therapeutic effect of N-acetylcysteine as an add-on to methadone maintenance therapy medication in outpatients with substance use disorders: A randomized, double-blind, placebo-controlled clinical trial","volume":"13","author":"Padoei","year":"2023","journal-title":"Brain Behav"},{"key":"2025090810351192000_15.9.e091631.27","doi-asserted-by":"crossref","first-page":"282","DOI":"10.9758\/cpn.2021.19.2.282","article-title":"Effectiveness of N-acetylcysteine in Treating Clinical Symptoms of Substance Abuse and Dependence: A Meta-analysis of Randomized Controlled Trials","volume":"19","author":"Chang","year":"2021","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"2025090810351192000_15.9.e091631.28","doi-asserted-by":"crossref","first-page":"13397","DOI":"10.1038\/s41598-021-92676-0","article-title":"The use of N-acetylcysteine in the prevention of hangover: a randomized trial","volume":"11","author":"Coppersmith","year":"2021","journal-title":"Sci Rep"},{"key":"2025090810351192000_15.9.e091631.29","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.drugalcdep.2017.12.005","article-title":"The effect of N-acetylcysteine on alcohol use during a cannabis cessation trial","volume":"185","author":"Squeglia","year":"2018","journal-title":"Drug Alcohol Depend"},{"key":"2025090810351192000_15.9.e091631.30","doi-asserted-by":"publisher","DOI":"10.1093\/alcalc\/agad044"},{"key":"2025090810351192000_15.9.e091631.31","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-016-1743-0","article-title":"Review and publication of protocol submissions to Trials \u2013 what have we learned in 10 years?","volume":"18","author":"Li","year":"2017","journal-title":"Trials"},{"key":"2025090810351192000_15.9.e091631.32","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-3-201302050-00583"},{"key":"2025090810351192000_15.9.e091631.33","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/npp.2011.182","article-title":"The Alcohol Clinical Trials Initiative (ACTIVE): Purpose and Goals for Assessing Important and Salient Issues for Medications Development in Alcohol Use Disorders","volume":"37","author":"Anton","year":"2012","journal-title":"Neuropsychopharmacol"},{"key":"2025090810351192000_15.9.e091631.34","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1465-3362.2008.00022.x","article-title":"Sample bias from different recruitment strategies in a randomised controlled trial for alcohol dependence","volume":"28","author":"Morley","year":"2009","journal-title":"Drug Alcohol Rev"},{"key":"2025090810351192000_15.9.e091631.35","unstructured":"Pettinati H , Donovan D , Ernst D , et al . Medical Management Treatment Manual: A Clinical Research Guide for Medically Trained Clinicians Providing Pharmacotherapy as Part of the Treatment for Alcohol Dependence. Bethesda: NIAAA, 2004."},{"key":"2025090810351192000_15.9.e091631.36","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.cct.2013.08.002","article-title":"The efficacy and biobehavioural basis of baclofen in the treatment of alcoholic liver disease (BacALD): study protocol for a randomised controlled trial","volume":"36","author":"Morley","year":"2013","journal-title":"Contemp Clin Trials"},{"key":"2025090810351192000_15.9.e091631.37","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2006.01555.x"},{"key":"2025090810351192000_15.9.e091631.38","doi-asserted-by":"publisher","DOI":"10.1093\/alcalc\/agu062"},{"key":"2025090810351192000_15.9.e091631.39","doi-asserted-by":"publisher","DOI":"10.1186\/1940-0640-8-19"},{"key":"2025090810351192000_15.9.e091631.40","unstructured":"First MB , Williams JBW , Karg RS , et al . Structured Clinical Interview for DSM5\u2014Research Version (SCID-5 for DSM-5, Research Version; SCID-5-RV). Arlington, VA: American Psychiatric Association, 2015."},{"key":"2025090810351192000_15.9.e091631.41","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.1988.tb00485.x"},{"key":"2025090810351192000_15.9.e091631.42","doi-asserted-by":"publisher","DOI":"10.1037\/0021-843X.91.3.199"},{"key":"2025090810351192000_15.9.e091631.43","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/acer.13278","article-title":"The Mini Alcohol Craving Experience Questionnaire: Development and Clinical Application","volume":"41","author":"Coates","year":"2017","journal-title":"Alcohol Clin Exp Res"},{"key":"2025090810351192000_15.9.e091631.44","doi-asserted-by":"crossref","unstructured":"Miller WR , TJ S , Longabaugh R . The Drinker Inventory of Consequences (DrInC): An Instrument for Assessing Adverse Consequences of Alcohol Abuse. Rockville, MD: NIAAA, 1995.","DOI":"10.1037\/e563232012-001"},{"key":"2025090810351192000_15.9.e091631.45","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.1991.tb01879.x"},{"key":"2025090810351192000_15.9.e091631.46","doi-asserted-by":"publisher","DOI":"10.1016\/0005-7967(94)00075-U"},{"key":"2025090810351192000_15.9.e091631.47","doi-asserted-by":"publisher","DOI":"10.1016\/S1389-9457(00)00065-4"},{"key":"2025090810351192000_15.9.e091631.48","unstructured":"Weathers FW , Blake DD , Schnurr PP . Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) . National Center for PTSD, 2013."},{"key":"2025090810351192000_15.9.e091631.49","doi-asserted-by":"publisher","DOI":"10.1177\/1073191114533814"},{"key":"2025090810351192000_15.9.e091631.50","doi-asserted-by":"publisher","DOI":"10.1111\/sltb.12084"},{"key":"2025090810351192000_15.9.e091631.51","doi-asserted-by":"crossref","DOI":"10.1186\/1471-244X-10-10","article-title":"Screening for personality disorder with the Standardised Assessment of Personality: Abbreviated Scale (SAPAS): further evidence of concurrent validity","volume":"10","author":"Hesse","year":"2010","journal-title":"BMC Psychiatry"},{"key":"2025090810351192000_15.9.e091631.52","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2005.53221.x"},{"key":"2025090810351192000_15.9.e091631.53","unstructured":"Mitrushina MN , Boone KL , D\u2019Elia L . Handbook of Normative Data for Neuropsychological Assessment. New York: Oxford University Press, 1999."},{"key":"2025090810351192000_15.9.e091631.54","doi-asserted-by":"publisher","DOI":"10.1037\/h0054651"},{"key":"2025090810351192000_15.9.e091631.55","doi-asserted-by":"publisher","DOI":"10.4081\/monaldi.2012.121"},{"key":"2025090810351192000_15.9.e091631.56","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.305.6846.160"},{"key":"2025090810351192000_15.9.e091631.57","doi-asserted-by":"publisher","DOI":"10.1249\/01.MSS.0000078924.61453.FB"},{"key":"2025090810351192000_15.9.e091631.58","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2006.10.001"},{"key":"2025090810351192000_15.9.e091631.59","first-page":"343","article-title":"SAFTEE: a technique for the systematic assessment of side effects in clinical trials","volume":"22","author":"Levine J","year":"1986","journal-title":"Psychopharmacol Bull"},{"key":"2025090810351192000_15.9.e091631.60","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.17.2003"},{"key":"2025090810351192000_15.9.e091631.61","doi-asserted-by":"crossref","first-page":"157","DOI":"10.15288\/jsas.2005.s15.157","article-title":"The COMBINE SAFTEE: a structured instrument for collecting adverse events adapted for clinical studies in the alcoholism field","volume":"Suppl","author":"Johnson","year":"2005","journal-title":"J Stud Alcohol Suppl"},{"key":"2025090810351192000_15.9.e091631.62","unstructured":"Pharmacovigilance responsibilities. 2017."},{"key":"2025090810351192000_15.9.e091631.63","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3102\/10769986024001070","article-title":"Sample size estimation for longitudinal designs with attrition","volume":"24","author":"Hedeker","year":"1999","journal-title":"Journal of Educational and Behavoral Statistics"},{"key":"2025090810351192000_15.9.e091631.64","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1111\/j.1530-0277.2010.01290.x","article-title":"Percentage of Subjects With No Heavy Drinking Days: Evaluation as an Efficacy Endpoint for AlcoholClinical Trials","volume":"34","author":"Falk","year":"2010","journal-title":"Alcoholism Clin &amp; Exp Res"},{"key":"2025090810351192000_15.9.e091631.65","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/acer.14018","article-title":"Maintenance of World Health Organization Risk Drinking Level Reductions and Posttreatment Functioning Following a Large Alcohol Use Disorder Clinical Trial","volume":"43","author":"Witkiewitz","year":"2019","journal-title":"Alcoholism Clin &amp; Exp Res"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-091631","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T17:35:31Z","timestamp":1757352931000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-091631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":65,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9,8]]},"published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1136\/bmjopen-2024-091631"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-091631","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]}}}